|
|
J Virol. 2007 June; 81(11): 5705–5713. Published online 2007 March 21. doi: 10.1128/JVI.00076-07. | PMCID: PMC1900270 |
Copyright © 2007, American Society for Microbiology Dysregulation of HER2/HER3 Signaling Axis in Epstein-Barr Virus-Infected Breast Carcinoma Cells ![[down-pointing small open triangle]](/corehtml/pmc/pmcents/x25BF.gif) Jiun-Han Lin,1 Ching-Hwa Tsai,2 Jan-Show Chu,3,4 Jeou-Yuan Chen,5 Kenzo Takada,6 and Jin-Yuh Shew1* Graduate Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan,1 Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan,2 Department of Pathology, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan,3 Department of Pathology, Taipei Medical University Hospital, Taipei 11031, Taiwan,4 Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan,5 Department of Tumor Virology, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan6 Received January 11, 2007; Accepted March 9, 2007. The role of Epstein-Barr virus (EBV) in the pathogenesis of breast cancer has been of long-standing interest to the field. Breast epithelial cells can be infected by EBV through direct contact with EBV-bearing lymphoblastoid cells, and EBV infection has recently been shown to confer breast cancer cells an increased resistance to chemotherapeutic drugs. In this study, we established EBV-infected breast cancer MCF7 and BT474 cells and demonstrated that EBV infection promotes tumorigenic activity of breast cancer cells. Firstly, we showed that the EBV-infected MCF7-A and BT474-A cells exhibited increased anchorage-independent growth in soft agar. The increased colony formation capacity in soft agar was associated with increased expression and activation of HER2/HER3 signaling cascades, as evidenced by the findings that the treatment of HER2 antibody trastuzumab (Herceptin), phosphatidylinositol 3-kinase inhibitor, or MEK inhibitor completely abolished the tumorigenic capacity. In the EBV-infected breast cancer cells, the expression of EBV latency genes including EBNA1, EBER1, and BARF0 was detected. We next showed that BARF0 alone was sufficient to efficiently up-regulate HER2/HER3 expression and promoted tumorigenic activity in MCF7 and BT474 cells by the use of both overexpression and small interfering RNA knock-down. Collectively, we demonstrated that EBV-encoded BARF0 promotes the tumorigenic activity of breast cancer cells through activation of HER2/HER3 signaling cascades. Epstein-Barr virus (EBV), a ubiquitous human gammaherpesvirus, is characterized by its association with an array of malignancies, including Burkitt's lymphoma, NK/T lymphoma, Hodgkin's disease, nasopharyngeal carcinoma (NPC), gastric carcinoma, and salivary gland carcinoma ( 50). Although multiple extrachromosomal copies of the viral episome are present in cells in the biopsy tissues, only a limited set of viral gene products is constitutively expressed since viruses exist in a latent status. The latent proteins comprise six EBV nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP), three latent membrane proteins (LMP-1, -2A, and -2B), two relatively abundant small, nonpolyadenylated RNAs (EBER1 and EBER2), and BamHI A rightward frame transcripts (BARTs) ( 29). EBV-encoded latent genes can induce B-cell transformation in vitro by altering cellular gene transcription and constitutively activating key cell-signaling pathways ( 71). One of the mechanisms for EBV to immortalize B lymphocytes is to up-regulate the expression of integrins ( 23). On the other hand, the increase of lysophosphatidic acid resulting from up-regulation of autotaxin is the main reason that EBV infection can promote the growth of Hodgkin lymphoma cells ( 3). Among the epithelial-derived malignancies, reinfection with EBV enhances the tumorigenicity of NPC cells ( 62). In gastric carcinoma cells, EBV promotes cell proliferation through the induction of insulin-like growth factor-mediated signaling in an autocrine fashion ( 24). In addition to the above-mentioned human malignancies, a growing body of evidence has indicated the possible involvement of EBV in other human cancers, such as carcinomas of breast and liver ( 50). The EBV genome has been detected in 0 to 50% of breast carcinomas ( 2, 5, 11, 12, 19, 22, 34, 48), and the variations may arise from the varying or uncertain specificity and sensitivity of the detection methods ( 16). In vitro, breast epithelial cells can be infected by direct contact with EBV-bearing lymphoblastoid cell lines ( 58). In addition, Arbach et al. have recently reported that the EBV infection of breast carcinoma cells confers increased resistance to chemotherapeutic drugs by facilitating the expression of a multidrug-resistance gene ( 2). These studies suggest a role of EBV in the pathogenesis of breast cancer and thus warrant further characterization. Breast carcinoma is the most frequently diagnosed malignancy of women worldwide. The epidermal growth factor receptor (EGFR) family-mediated signaling pathway is known to play a crucial role in breast carcinoma formation and development. There are four members of the EGFR family: HER1 (EGFR), HER2 (also known as neu or ErbB2), HER3, and HER4 ( 68, 73). Amplification and overexpression of HER2 is observed in 20 to 30% of human breast cancers and is correlated with a poor prognosis ( 55, 56). Recently, increased expression of HER3 in breast cancer has been linked to decreased survival. Overexpression of HER3 is noted in about 20% of all breast cancers and is usually coexpressed with HER2 ( 1, 4, 44, 49, 66). Structurally, HER2 is an unliganded type of receptor while HER3 is deficient in kinase activity. However, coexpression and the formation of a HER2/HER3 heterodimer allow the efficient activation of potent oncogenic signaling cascades ( 10, 20), which may be particularly important in driving the malignant transformation and progression of mammary tumors ( 1). To explore the involvement of EBV in breast cancer, we use the MCF7 and BT474 breast cell lines as study models for EBV infection and follow the biological outcomes of these two cell lines. Of note, EBV infection significantly increases the anchorage-independent growth of both cell lines, which is mediated through the overexpression of HER2 and HER3 followed by the activation of downstream extracellular signal-regulated kinase (ERK) and Akt. Most importantly, we further show that BARF0 alone is sufficient to confer on breast cancer cells increased transforming activity. Cell culture. Human breast carcinoma MCF7 and BT474 cell lines were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium-F12 (Gibco BRL) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Biological Industries), 100 units/ml penicillin, and 100 μg/ml streptomycin (Gibco BRL) at 37°C in a 5% CO2 humidified atmosphere. Trastuzumab (Herceptin) was purchased from Genentech, Inc. (South San Francisco, CA). LY294002 and U0126 were obtained from Calbiochem (San Diego, CA). Establishment of EBV-infected MCF7 and BT474 cells. MCF7 and BT474 cells were infected with recombinant EBV (rEBV) (containing the neomycin resistance [Neo r] genes) ( 54) using a “cell-to-cell” infection procedure ( 6). Briefly, MCF7 and BT474 cells were cocultured with the rEBV-infected Akata cells which had been pretreated with 0.8% (vol/vol) rabbit anti-human immunoglobulin G (Cappel, Aurora, OH) to induce virus production. The plate was centrifuged at 2,000 × g for 5 min and then incubated at 37°C for 24 h. After incubation, the culture was washed five times with phosphate-buffered saline to remove residual Akata cells, and fresh medium was added. On day 3, the cells were reseeded into 24-well plates in culture medium containing G418 (700 μg/ml) (Gibco BRL) for selection of pooled rEBV-infected clones. Plasmids, transfection, and cell cloning. The EBNA1 plasmid pCEP4 (Invitrogen) carries the simian virus 40 (SV40) promoter-driven hygromycin resistance (Hyg r) gene and the EBNA1 gene. The pcDNA3 and pcDNA3.1-Hyg(+) (Invitrogen) plasmids carry the SV40 promoter-driven Neo r and Hyg r genes, respectively. The pcDNA3-HA (where HA is hemagglutinin) plasmid carries the SV40 promoter-driven Neo r and the HA-tagged gene. BARF0 was amplified from the genomic DNA from Akata cells by PCR using the primers 5′-CGGGATCCCGGAGAGGCGGGAATGGCC-3′ (BamHI-BARF0-F, from nucleotides [nt] 160459 to 160475 of the B95.8 sequence) and 5′-GGAATTCCTTAATGAAGAGAATCAATAGCGTGT-3′ (EcoRI-BARF0-R, from nt 160994 to 160970 of the B95.8 sequence). The PCR-amplified fragment of BARF0 was digested with BamHI and EcoRI and ligated into BamHI/EcoRI-digested pcDNA3-HA to generate pcDNA3-HA-BARF0. The pcDNA3-HA-BARF0 plasmid contained the BARF0 open reading frame, nt 160470 to 160994 of the B95.8 strain. The EBER plasmid was constructed as described previously ( 32). To construct a small interfering RNA (siRNA) against BARF0, the oligonucleotide 5′-CTGGCGGACTTCATTCTCA-3′ (from nt 160704 to 160722 of the B95.8 sequence), designed using a program available online ( https://www.genscript.com/ssl-bin/app/rnai), was annealed with its antisense strand and cloned into pSUPERpuro plasmid (OligoEngine, Seattle, WA), yielding pSUPERpuroBARF0. All constructs were confirmed by automated nucleotide sequencing. Cells were seeded in a 3.5-cm petri dish and transfected with 4 μg of plasmid DNA using Lipofectamine 2000 transfection reagent (Invitrogen), according to the manufacturer's protocol. The transfected cells were selected in culture medium containing 200 μg/ml of hygromycin B, 700 μg/ml of G418, or 1 μg/ml puromycin (Gibco BRL) for 2 to 3 weeks. Reverse transcription (RT)-PCR analysis. Total RNA was isolated from cells using REzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol and converted to cDNA using PowerScript reverse transcriptase (BD Biosciences) in the presence of random hexamers (BD Biosciences). The cDNA was used as template for PCR in the presence of primer pairs specific for HER2, HER3, and EBV transcripts such as EBNA1, EBER1, BARF0, RK-BARF0, EBNA2, LMP1, LMP2A, and Zta. Sequences of primer pairs used for detection of mRNA expression were as follows (described as 5′ end primer and 3′ end primer, respectively); HER2, 5′-ATGTATTTGATGGTGACCTG-3′ and 5′-TCTTGGCCCTTTCCAGAGTG-3′; HER3, 5′-GGGAGCCGCTTCCAGACT-3′ and 5′-TTGAGGCCGGTGATCAGAAA-3′ ( 47); EBNA1, 5′-GATGAGCGTTTGGGAGAGCTGATTCTGCA-3′ (gEBNA1-a, from nt 67511 to 67539 of the B95.8 sequence) and 5′-TCCTCGTCCATGGTTATCAC-3′ (gEBNA1-b, from nt 108075 to 108056 of the B95.8 sequence) ( 60); EBER1, 5′-CTACGCTGCCCTAGAGGTTTTGCTA-3′ (EBER1-1, from nt 6634 to 6658 of the B95.8 sequence) and 5′-ATGCGGACCACCAGCTGGTACTTGA-3′ (EBER1-2, from nt 6790 to 6766 of the B95.8 sequence) ( 61); BARF0, 5′-TGTCCAGCGCTCTGGTCG-3′ (BARF-LLW5′, from nt 160586 to 160603 of the B95.8 sequence) and 5′-CCACGGCAACCCTTCCAC-3′ (BARF-2, from nt 160812 to 160795 of the B95.8 sequence) ( 31); RK-BARF0, 5′-CGCTGAGGACTGCAAACTCC-3′ (RKBF0-P, from nt 160245 to 160264 of the B95.8 sequence) and 5′-CCATGCTATCGGTGCAACG-3′ (RKBF0-FL, from nt 160512 to 160494 of the B95.8 sequence) ( 64); EBNA2, 5′-ACTTTGAGCCACCCACAGTAACCA-3′ (EBNA2-1, from nt 47912 to 47935 of the B95.8 sequence) and 5′-TGGAGTGTCTGACAGTTGTTCCTG-3′ (EBNA2-2, from nt 48635 to 48612 of the B95.8 sequence) ( 7); LMP1, 5′-CTTCAGAAGAGACCTTCTCT-3′ (LMP1-1, from nt 169262 to 169243 of the B95.8 sequence) and 5′-ACAATGCCTGTCCGTGCAAA-3′ (LMP1-2, from nt 169081 to 169100 of the B95.8 sequence) ( 63); LMP2A, 5′-ATGACTCATCTCAACACATA-3′ (LMP2A-F, from nt 166874 to 166893 of the B95.8 sequence) and 5′-CATGTTAGGCAAATTGCAAA-3′ (LMP2A-R, from nt 381 to 362 of the B95.8 sequence) ( 28); Zta, 5′-TTCCACAGCCTGCACCAGTG-3′ (Z1, from nt 102719 to 102700 of the B95.8 sequence) and 5′-GGCAGCAGCCACCTCACGGT-3′ (Z2, from nt 102330 to 102341 and 102426 to 102433 of the B95.8 sequence) ( 63). The S26 was used as an internal control ( 65). The oligonucleotides 5′-CCGTGCCTCCAAGATGACAAAG-3′ and 5′-ACTCAGCTCCTTACATGGGCTT-3′ are a primer pair specific for S26. Western blotting. Cells were lysed into radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 2 mM EDTA, 100 μM Na 3VO 4, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 20 μg/ml aprotinin, and 20 μg/ml leupeptin), and cell lysates were prepared for Western blot analysis against an NPC patient's serum (used for detection of EBNA1) ( 6), anti-EBNA2 (PE2) ( 70), anti-LMP1 (S12) ( 41), anti-α-tubulin (CP-06; Oncogene), anti-HER1 (Sc-03; Santa Cruz, CA), anti-HER2 (Ab-3; Oncogene), anti-HER3 (Sc-285; Santa Cruz, CA), anti-HER4 (Sc-283; Santa Cruz, CA), anti-ERK1/2 (Cell Signaling Technology), anti-phospho-ERK1/2 (Cell Signaling Technology), anti-Akt (Cell Signaling Technology), anti-phospho-Akt (Ser473) (Cell Signaling Technology), anti-p85 (phosphatidylinositol 3-kinase [PI3K] subunit) (Upstate, Lake Placid, NY), or anti-pTyr (BD Biosciences), followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies; detection was performed using enhanced chemiluminescence reagent (Blossom Biotechnologies, Inc.). Protein expression levels were quantified using a UVP AutoChemi Image System and normalized with α-tubulin expression levels. Immunoprecipitations. Cells were lysed in a buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 100 μM Na3VO4, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 20 μg/ml aprotinin, and 20 μg/ml leupeptin. Cell lysate (500 μg) was precipitated by overnight incubation with 1 μg of anti-HER2 antibody at 4°C. Twenty-five microliters of protein A-Sepharose (Amersham Biosciences) was added to the solution. After incubation for 60 min at 4°C, the immunoprecipitated complexes were collected by centrifugation and subjected to Western blot analyses. Anchorage-independent growth. Anchorage independence of growth was determined by assaying colony formation in soft agar. Briefly, MCF7 cells (1 × 104) and BT474 cells (1 × 105) were suspended in Dulbecco's modified Eagle's medium-F12 medium containing 10% FBS and 0.33% low-melting-temperature agarose and layered over the solidified modified Eagle's medium-10% FBS-0.3% tryptose phosphate broth-0.5% agarose. After 14 days, colonies were then stained with 0.05% crystal violet, and colonies larger than 60 μm were counted. Reporter gene assays. The MCF7-Neo r and MCF7-HA-BARF0 cells were plated at a density of 1 × 10 5 cells per well (12-well plate). After 24 h, the cells were cotransfected with pGL3-erb3 ( 75) or pNulit ( 67) along with the Renilla luciferase plasmid phRL-TK (1:10 ratio with target reporter) (Promega) using the Lipofectamine 2000 transfection reagent (Invitrogen). Forty-eight hours posttransfection, luciferase activities were measured with a Dual-Glo Luciferase assay system (Promega). Each transfection was performed in triplicate, and experiments were repeated three times. The results were presented as relative activation by calculating the ratio of normalized luciferase activity of the MCF7-HA-BARF0 to that of the MCF7-Neo r cells. EBV-infected breast cancer cells display type I latency. To investigate the potential effects of EBV infection in human breast cancer, two human breast cancer cell lines, MCF7 and BT474, were infected with an rEBV (rAkata EBV) which contains the Neo r gene ( 54). By a “cell-to-cell” infection procedure previously described ( 6), EBV-harboring cell clones were enriched by selection against G418. Genomic PCR assays were performed to verify the presence of EBV in the pooled Neo r clones. PCR was performed using primers specifically amplifying three regions of the EBV genome: BamHI W, BZLF1, and BNLF1. All the PCR results indicated that EBV DNA BamHI W, BZLF1, and BNLF1 were detected in MCF7-A (EBV-infected MCF7 cells) and BT474-A (EBV-infected BT474 cells) but not in the vector control MCF7-Neo r and BT474-Neo r cells (data not shown). The status of EBV is known to lead to different gene expression patterns. We therefore determined the viral gene expression in the EBV-infected breast cancers cells by RT-PCR assays. As shown, the EBV latency I products such as EBNA1 and BARF0 transcripts and the EBER1 RNAs were readily detected but not RK-BARF0, EBNA2, LMP1, LMP2A, and Zta transcripts (Fig. ), indicating the status of EBV as type I latency in both cell lines. Consistent with these findings, Western blot analysis confirmed that EBNA1 protein but not EBNA2 or LMP1 was expressed in MCF7-A and BT474-A cells (Fig. ). We further determined the EBV copy numbers in each of the recipient cells by real-time PCR using Raji cells (50 copies of EBV DNA per cell) ( 59) as a standard. As a result, approximately one copy of EBV genome DNA was detected in each single MCF7-A and BT474-A cell (data not shown). EBV enhances breast cancer cell growth in soft agar. To study the effect of EBV infection on breast cancer cells, we assessed the capacity for anchorage-independent growth of the EBV-infected breast cancer cells by testing their ability to form colonies while suspended in soft agar. Like most transformed cells, the parental MCF7 and BT474 cells formed a number of colonies after 2 weeks of growth in soft agar. Under the same conditions, MCF7-A and BT474-A cells exhibited an increased capacity for soft agar colony formation, with more than a twofold increase in colonies formed (P < 0.05), whereas there was no change in the control vector-harboring cells (Fig. ). These data suggest that EBV may enhance the tumorigenic capacity of breast cancer cells. EBV infection leads to upregulation of HER2 and HER3 in breast cancer cells. We next investigated the mechanisms through which EBV enhanced breast cancer cell anchorage-independent growth. HER2 axis is one of the major signaling pathways that go awry in the pathogenic development of breast cancer. Overexpression of HER2 is found in 20 to 30% of cases of human breast cancer; moreover, it is correlated with a poor prognosis ( 55, 56). In vitro, ectopic expression of HER2 in breast carcinoma cells can promote anchorage-independent growth and enhance tumorigenicity ( 18, 45). We examined the status of HER2 in EBV-infected MCF7 and BT474 cells. Notably, HER2 was expressed at a strikingly elevated level in both MCF7-A and BT474-A cells, as demonstrated by RT-PCR analysis (Fig. ). The HER2 protein level was also significantly increased (Fig. ). Because HER2 is devoid of an activating ligand, it forms heterodimers with HER1, HER3, or HER4 to relay signals downstream upon ligand binding ( 68). We also examined the expression status of HER1, HER3, and HER4 and found that HER3 expression was significantly enhanced at both transcription and translation levels in the EBV-infected cells, whereas the expression of HER1 and HER4 remained unchanged (Fig. and ). The formation of the HER2/HER3 heterodimer in these cells was detected by coimmunoprecipitation. When HER2 was immunoprecipitated from the MCF7-A cell lysates, a robust increase in the amount of HER3 was detected in the immunoprecipitates (Fig. ). Concomitantly, a dramatic increase of tyrosine phosphorylation of HER2 was observed, along with increased binding of p85 (PI3K subunit) to HER2/HER3 complex. All of these results suggest that EBV infection not only increases the expression but also enhances the functional activity of HER2/HER3. ERK and PI3K are activated downstream of the HER2/HER3 signaling pathway to enhance tumorigenic activity in EBV-infected breast cancer cells. We next examined the downstream signals of the HER2/HER3 axis in EBV-infected MCF7 and BT474 breast cancer cells. As shown in Fig. , the phosphorylation of ERK and Akt, representing the major proliferative and survival pathways downstream of the HER2/HER3 activation, was profoundly increased in MCF7-A and BT474-A cells but not in the control cells. To attest that ERK and Akt were activated downstream of HER2/HER3 but not other signaling pathways, these cells were treated with trastuzumab, a well-known monoclonal antibody directed against the extracellular domain of and an effective inhibitor of HER2. Upon treatment with trastuzumab (10 μg/ml) for a designated time, cell lysates were prepared and subjected to immunoblotting analysis. As shown in Fig. , trastuzumab treatment suppressed phosphorylation of ERK and Akt in MCF7-A cells in a time-dependent manner (Fig. ), without affecting the protein levels of these two kinases. These results thus demonstrate an essential role of activation of HER2/HER3 signaling for efficient activation of ERK and Akt in EBV-infected breast cancer cells. We further evaluated the role of the HER2/HER3 signaling pathway in the EBV-enhanced transforming capability in the MCF7-A and BT474-A cells. An anchorage-independent assay of growth in soft agar was performed in the presence of trastuzumab. As shown in Fig. , trastuzumab treatment efficiently reduced the number of colonies formed by MCF7-A cells in soft agar to that observed in MCF7 and MCF7-Neor cells. In addition, U0126 (a MEK inhibitor) and LY294002 (a PI3K inhibitor) also efficiently suppressed EBV-mediated anchorage-independent growth. These data further substantiated that the EBV-mediated transforming capability is mediated through activation of the HER2/HER3 signaling axis and subsequent activation of both ERK and Akt. EBV-encoded BARF0 enhances HER2 and HER3 expression. Because expression of EBNA1, EBER1, and BARF0 was detected in EBV-infected MCF7 and BT474 cells (Fig. ), we further investigated which of the EBV-encoded products could be attributed to the enhanced expression and activation of HER2 and HER3. MCF7 cells were transfected with individual EBNA1-, EBER-, and BARF0-expressing plasmids, and transfectants harboring the designated EBV genes were established by antibiotic selection. Pooled clones stably expressing specific products at levels similar to the MCF7-A cells were selected for RT-PCR analysis of HER2 and HER3 expression (Fig. ). Of note, the transcripts of these two receptors were significantly upregulated in MCF7-HA-BARF0 (BARF0-transfected MCF7 cells), whereas MCF7-EBNA1 and MCF7-EBERs (EBNA1- and EBER-transfected MCF7 cells) expressed HER2 and HER3 at levels similar to those of parental cells. Consistently, the protein levels of HER2 and HER3 were also robustly increased in BARF0 transfectants compared to levels of parental cells (Fig. ). To further corroborate that BARF0 is responsible for EBV-mediated upregulation of HER2 and HER3 in breast cancer cells, we performed targeted knock-down of BARF0 expression in MCF7-A cells. After transfection of pSuperpuroBARF0, the vector carrying the siRNA specifically targeting toward BARF0, the transfected MCF7-A cells (MCF7-A-siBARF0) were selected for puromycin resistance. The expression of BARF0 was fully eliminated in MCF7-A-siBARF0 but remained unaffected in vector-harboring MCF7-A-pSuper cells (Fig. ). The knock-down was specific toward BARF0 for the expression of EBER1, and EBNA1 remained highly expressed in the MCF7-A-siBARF0 cells. As shown in Fig. , targeted knock-down of BARF0 in MCF7-A cells effectively reversed the expression of HER2 and HER3 to a basal level similar to that observed in the parental MCF7 cells. These data thus suggest that BARF0 may activate the transcription of HER2 and HER3 in MCF7 cells. This notion was further supported by promoter assays. The HER2 promoter-containing luciferase reporter plasmid (pNulit) or the HER3 promoter-containing luciferase reporter plasmid (pGL3-erb3) was transfected into MCF7-Neor or MCF7-HA-BARF0 cells, respectively. As shown, the luciferase activities driven by HER2 and HER3 promoters were greatly induced by 9.1-fold and 8.3-fold, respectively, in the MCF7-HA-BARF0 cells compared to levels in MCF7-Neor cells (Fig. ). BARF0 enhanced breast cancer cell growth in soft agar through HER2/HER3 signaling. Next, we examined whether BAFR0 could activate HER2/HER3 signaling. MCF7-HA-BARF0 and MCF7-Neor cells were treated with vehicle control (dimethyl sulfoxide [DMSO]) and trastuzumab for 48 h, and cell lysates were prepared for Western blot analyses. As shown in Fig. , ERK and Akt were phosphorylated at higher levels in MCF7-HA-BARF0 than in the MCF7-Neor cells, and the treatment with trastuzumab blocked the phosphorylation of both ERK and Akt. As controls, the treatment with LY294002 and U0126 blocked the phosphorylation of ERK and Akt, respectively, in MCF7-HA-BARF0 cells. These data suggest that BARF0 alone is sufficient to induce the activation of HER2/HER3 which, in turn, drives the activation of ERK and Akt. We further determined the involvement of BARF0 in the process of malignant transformation of EBV-harboring breast cancer cells. An anchorage-independent growth assay was performed to measure the capacity of MCF7-HA-BARF0 cells for colony formation in soft agar. After culturing for 14 days, MCF7-HA-BARF0 cells formed significantly more colonies than the control MCF7-Neor cells, and the BARF0-elicited anchorage-independent growth in soft agar was abrogated when MCF7-HA-BARF0 cells were treated with trastuzumab (Fig. ). In agreement with these findings, treatment with LY294002 or U0126 also abolished BARF0-mediated colony-forming activity. We thus conclude that BARF0 facilitates tumorigenic activity in breast cancer cells by activating HER2/HER3 signaling axis. EBV infection has been implicated in the pathogenic development of a variety of human cancers including NPC and stomach cancer ( 27, 39, 46, 69). It is of particular interest that EBV employs strategies different from those of other tumor viruses to enhance the transforming activities of the infected cells. EBV has been shown to directly promote cell cycle progression ( 37), to enhance the cancer cell growth through induction of interleukin-9 and insulin-like growth factor 1 ( 24, 25), to inhibit apoptosis by increasing the expression of antiapoptotic protein bcl-2 in B cells or up-regulating the expression of A20 in epithelial cells ( 17, 35), to activate the expression of a variety of matrix metalloprotinases, and to promote cell invasiveness ( 39, 69). Of interest, the EBV genome and its viral products have been commonly detected in many human carcinoma biopsies including breast cancer; however, the role of EBV in breast malignancy has only recently been studied ( 2, 5, 50). We have previously established a cell-to-cell cocultured system which has allowed us successfully to infect epithelial cells in vitro by EBV ( 6). By this cell-to-cell infection procedure, we obtained in this study two EBV-infected breast cancer cell lines and demonstrated the EBV-mediated overactivation of the HER2/HER3 signaling axis in these EBV-infected breast cancer cells. Protein tyrosine kinases represent a major class of oncogene products. EBV-encoded gene products have been shown to activate a number of receptor and nonreceptor tyrosine kinases and control many crucial events in cell proliferation, differentiation, and development ( 9, 14, 21, 36, 38, 40, 42, 53). In particular, LMP1 can up-regulate the expression of c-Met through the activation of transcription factor Ets-1 and promote the expression of vascular endothelial growth factor via NF-κB activation ( 21, 43). LMP1 has also been shown to up-regulate the expression of EGFR both in vivo and in vitro ( 42, 53). The EB viral latent membrane protein LMP2A can act as a survival factor by inhibiting transforming growth factor β1-mediated apoptosis and promote cell survival through the PI3K pathway ( 14). LMP2A also activates Syk in epithelial cells and promotes cell migration ( 40). The viral lytic transactivators Zta and Rta can induce the expression of tyrosine kinase TKT and c-Mer, respectively ( 36, 38). On the other hand, ectopic EBNA1 expression has been shown to suppress the expression and transforming activity of the HER2/ neu oncogene in HER2/ neu-overexpressing human ovarian cancer cells and to sensitize cells to paclitaxel (Taxol)-induced apoptosis ( 8, 9). In this study, we report for the first time that EBV infection leads to the dysregulation of the HER2/HER3 signaling axis in breast cancer cells. Furthermore, we demonstrate that EBV-elicited activation of the HER2/HER3 cascade ushers the phosphorylation of ERK and Akt, which may in turn stimulate cell anchorage-independent growth in soft agar. It has been reported that EBV infection may contribute to paclitaxel resistance in breast carcinoma cell lines due to the increased expression of MDR1 ( 2). In this study, we have also found that EBV-infected MCF7 and BT474 cells displayed increased resistance to paclitaxel-induced apoptosis, and the resistance phenotype is associated with a concomitant increase in HER2-mediated phosphorylation of p34(Cdc2) at tyrosine-15 (data not shown). These data are in consistent with previous findings that overexpression of HER2 or MDR1 renders breast cancer cells highly resistant to paclitaxel ( 72). These findings therefore suggest that EBV infection may impede clinical chemotherapy in breast cancers by inducing drug resistance. To further dissect the molecular mechanisms through which EBV up-regulates HER2/HER3 signaling in breast cancer cells, we examined the involvement of the major EBV gene products expressed in the infected cells, including EBNA1, EBER1, and BARF0 (Fig. ). Notably, we found that BARF0 alone confers increased expression and activation of HER2 and HER3 in breast cancer cells (Fig. ). In addition, using siRNA specifically targeted to knock down the expression of BARF0 in the EBV-infected MCF7-A cells reversed EBV-elicited HER2 and HER3 expression, demonstrating that BARF0 alone is sufficient to induce the constitutive activation of the HER family in EBV-infected breast cancer cells. BARF0 belongs to the BART family ( 51). Other than BARF0, RK-BARF0, RPMS1, and A73 also represent the main products of these transcripts ( 13, 15, 26, 30, 33, 51, 52, 57). The transcripts of this differentially spliced RNA family share unique characteristics, and their expression is constantly detected in several types of EBV-infected cells and EBV-associated malignant biopsies ( 64). Among them, RK-BARF0 is proposed to encode a 279-amino-acid protein with a possible endoplasmic reticulum-targeting sequence. It interacts with Notch, and reduced expression of Notch is found in EBV-positive cell lines that correlate with RK-BARF0 expression ( 33). RPMS1 is proposed to encode a nuclear protein named RPMS. It interacts both with CBF1 and corepressor CIR and interferes with NotchIC and EBNA2 activation of CBF1-repressed promoters ( 57, 74). It has been demonstrated that A73, a cytoplasmic protein, can interact with the cell protein RACK1 ( 57). In contrast to BARF0, RK-BARF0 (Fig. ) and RPMS1 transcripts (data not shown) were not detected in MCF7-A or BT474-A cells by RT-PCR. Actually, it is still not clear how the BART family would contribute to EBV infection or pathology. In this study, we provide another line of evidence that BARF0 can enhance the cell clonability through dysregulation of the HER kinase family. Importantly, we showed that two main downstream signals of the HER family, PI3K and ERK, are activated and both are required for BARF0-elicited soft agar clonability (Fig. ). The molecular mechanisms through which BARF0 influences the expression of HER2 and HER3 remain for future study. In summary, our data suggest that BARF0-mediated induction of HER2 and HER3 expression may enhance the tumorigenic activity of breast cancer cells by activating HER2/HER3 signaling cascades. These data provide insights into the roles of EBV and BARF0 in EBV-associated malignancies, in particular, breast cancer. We thank Mien-Chie Hung of the University of Texas M.D. Anderson Cancer Center for kindly providing pNulit plasmid and Frederick E. Domann of the University of Iowa for kindly providing pGL3-erb3 plasmid. This work was supported by the National Science Council, Taiwan (grants NSC 92-2321-B-002-017 and NSC 95-2320-B-002-056). 1. Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821. [PubMed] 2. Arbach, H., V. Viglasky, F. Lefeu, J. M. Guinebretiere, V. Ramirez, N. Bride, N. Boualaga, T. Bauchet, J. P. Peyrat, M. C. Mathieu, S. Mourah, M. P. Podgorniak, J. M. Seignerin, K. Takada, and I. Joab. 2006. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J. Virol. 80:845-853. [PubMed] 3. Baumforth, K. R., J. R. Flavell, G. M. Reynolds, G. Davies, T. R. Pettit, W. Wei, S. Morgan, T. Stankovic, Y. Kishi, H. Arai, M. Nowakova, G. Pratt, J. Aoki, M. J. Wakelam, L. S. Young, and P. G. Murray. 2005. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106:2138-2146. [PubMed] 4. Bobrow, L. G., R. R. Millis, L. C. Happerfield, and W. J. Gullick. 1997. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur. J. Cancer 33:1846-1850. [PubMed] 5. Bonnet, M., J. M. Guinebretiere, E. Kremmer, V. Grunewald, E. Benhamou, G. Contesso, and I. Joab. 1999. Detection of Epstein-Barr virus in invasive breast cancers. J. Natl. Cancer Inst. 91:1376-1381. [PubMed] 6. Chang, Y., C. H. Tung, Y. T. Huang, J. Lu, J. Y. Chen, and C. H. Tsai. 1999. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J. Virol. 73:8857-8866. [PubMed] 7. Cherney, B. W., C. Sgadari, C. Kanegane, F. Wang, and G. Tosato. 1998. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 91:2491-2500. [PubMed] 8. Chuang, T. C., Y. J. Lee, J. Y. Liu, Y. S. Lin, J. W. Li, V. Wang, S. L. Law, and M. C. Kao. 2003. EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. Biochem. Biophys. Res. Commun. 307:653-659. [PubMed] 9. Chuang, T. C., T. D. Way, Y. S. Lin, Y. C. Lee, S. L. Law, and M. C. Kao. 2002. The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene. FEBS Lett. 532:135-142. [PubMed] 10. Citri, A., K. B. Skaria, and Y. Yarden. 2003. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. 284:54-65. [PubMed] 11. Deshpande, C. G., S. Badve, N. Kidwai, and R. Longnecker. 2002. Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. Lab. Investig. 82:1193-1199. [PubMed] 12. Fina, F., S. Romain, L. Ouafik, J. Palmari, F. Ben Ayed, S. Benharkat, P. Bonnier, F. Spyratos, J. A. Foekens, C. Rose, M. Buisson, H. Gerard, M. O. Reymond, J. M. Seigneurin, and P. M. Martin. 2001. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br. J. Cancer. 84:783-790. [PubMed] 13. Fries, K. L., T. B. Sculley, J. Webster-Cyriaque, P. Rajadurai, R. H. Sadler, and N. Raab-Traub. 1997. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J. Virol. 71:2765-2771. [PubMed] 14. Fukuda, M., and R. Longnecker. 2004. Latent membrane protein 2A inhibits transforming growth factor-β1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J. Virol. 78:1697-1705. [PubMed] 15. Gilligan, K. J., P. Rajadurai, J. C. Lin, P. Busson, M. Abdel-Hamid, U. Prasad, T. Tursz, and N. Raab-Traub. 1991. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J. Virol. 65:6252-6259. [PubMed] 16. Glaser, S. L., J. L. Hsu, and M. L. Gulley. 2004. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol. Biomarkers Prev. 13:688-697. [PubMed] 17. Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115. [PubMed] 18. Hermanto, U., C. S. Zong, and L. H. Wang. 2001. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 20:7551-7562. [PubMed] 19. Herrmann, K., and G. Niedobitek. 2003. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res. 5:R13-R17. [PubMed] 20. Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas III, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100:8933-8938. [PubMed] 21. Horikawa, T., T. S. Sheen, H. Takeshita, H. Sato, M. Furukawa, and T. Yoshizaki. 2001. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am. J. Pathol. 159:27-33. [PubMed] 22. Huang, J., H. Chen, L. Hutt-Fletcher, R. F. Ambinder, and S. D. Hayward. 2003. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J. Virol. 77:13267-13274. [PubMed] 23. Huang, S., D. Stupack, A. Liu, D. Cheresh, and G. R. Nemerow. 2000. Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of αvintegrins. Oncogene 19:1915-1923. [PubMed] 24. Iwakiri, D., Y. Eizuru, M. Tokunaga, and K. Takada. 2003. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res. 63:7062-7067. [PubMed] 25. Iwakiri, D., T. S. Sheen, J. Y. Chen, D. P. Huang, and K. Takada. 2005. Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 24:1767-1773. [PubMed] 26. Karran, L., Y. Gao, P. R. Smith, and B. E. Griffin. 1992. Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells. Proc. Natl. Acad. Sci. USA 89:8058-8062. [PubMed] 27. Kassis, J., A. Maeda, N. Teramoto, K. Takada, C. Wu, G. Klein, and A. Wells. 2002. EBV-expressing AGS gastric carcinoma cell sublines present increased motility and invasiveness. Int. J. Cancer 99:644-651. [PubMed] 28. Kerr, B. M., A. L. Lear, M. Rowe, D. Croom-Carter, L. S. Young, S. M. Rookes, P. H. Gallimore, and A. B. Rickinson. 1992. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187:189-201. [PubMed] 29. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus, p. 2511-2573. In B. N. Fields, D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA. 30. Kienzle, N., M. Buck, S. Greco, K. Krauer, and T. B. Sculley. 1999. Epstein-Barr virus-encoded RK-BARF0 protein expression. J. Virol. 73:8902-8906. [PubMed] 31. Kienzle, N., T. B. Sculley, L. Poulsen, M. Buck, S. Cross, N. Raab-Traub, and R. Khanna. 1998. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J. Virol. 72:6614-6620. [PubMed] 32. Komano, J., S. Maruo, K. Kurozumi, T. Oda, and K. Takada. 1999. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J. Virol. 73:9827-9831. [PubMed] 33. Kusano, S., and N. Raab-Traub. 2001. An Epstein-Barr virus protein interacts with Notch. J. Virol. 75:384-395. [PubMed] 34. Labrecque, L. G., D. M. Barnes, I. S. Fentiman, and B. E. Griffin. 1995. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res. 55:39-45. [PubMed] 35. Laherty, C. D., H. M. Hu, A. W. Opipari, F. Wang, and V. M. Dixit. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J. Biol. Chem. 267:24157-24160. [PubMed] 36. Li, Y., N. P. Mahajan, J. Webster-Cyriaque, P. Bhende, G. K. Hong, H. S. Earp, and S. Kenney. 2004. The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1. J. Virol. 78:11778-11785. [PubMed] 37. Lo, A. K., K. W. Lo, S. W. Tsao, H. L. Wong, J. W. Hui, K. F. To, D. S. Hayward, Y. L. Chui, Y. L. Lau, K. Takada, and D. P. Huang. 2006. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173-180. [PubMed] 38. Lu, J., S. Y. Chen, H. H. Chua, Y. S. Liu, Y. T. Huang, Y. Chang, J. Y. Chen, T. S. Sheen, and C. H. Tsai. 2000. Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta. J. Virol. 74:7391-7399. [PubMed] 39. Lu, J., H. H. Chua, S. Y. Chen, J. Y. Chen, and C. H. Tsai. 2003. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res. 63:256-262. [PubMed] 40. Lu, J., W. H. Lin, S. Y. Chen, R. Longnecker, S. C. Tsai, C. L. Chen, and C. H. Tsai. 2006. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J. Biol. Chem. 281:8806-8814. [PubMed] 41. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol. 55:710-720. [PubMed] 42. Miller, W. E., H. S. Earp, and N. Raab-Traub. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69:4390-4398. [PubMed] 43. Murono, S., H. Inoue, T. Tanabe, I. Joab, T. Yoshizaki, M. Furukawa, and J. S. Pagano. 2001. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA 98:6905-6910. [PubMed] 44. Naidu, R., M. Yadav, S. Nair, and M. K. Kutty. 1998. Expression of c-erbB3 protein in primary breast carcinomas. Br. J. Cancer 78:1385-1390. [PubMed] 45. Nanni, P., S. M. Pupa, G. Nicoletti, C. De Giovanni, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, R. De Vecchi, A. M. Invernizzi, E. Di Carlo, P. Musiani, G. Forni, S. Menard, and P. L. Lollini. 2000. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87:186-194. [PubMed] 46. Nishikawa, J., S. Imai, T. Oda, T. Kojima, K. Okita, and K. Takada. 1999. Epstein-Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression. J. Virol. 73:1286-1292. [PubMed] 47. Pawlowski, V., F. Revillion, M. Hebbar, L. Hornez, and J. P. Peyrat. 2000. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6:4217-4225. [PubMed] 48. Perrigoue, J. G., J. A. den Boon, A. Friedl, M. A. Newton, P. Ahlquist, and B. Sugden. 2005. Lack of association between EBV and breast carcinoma. Cancer Epidemiol. Biomarkers Prev. 14:809-814. [PubMed] 49. Quinn, C. M., J. L. Ostrowski, S. A. Lane, D. P. Loney, J. Teasdale, and F. A. Benson. 1994. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 25:247-252. [PubMed] 50. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2575-2627. In B. N. Fields, D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA. 51. Sadler, R. H., and N. Raab-Traub. 1995. Structural analyses of the Epstein-Barr virus BamHI A transcripts. J. Virol. 69:1132-1141. [PubMed] 52. Schroder, W., N. Kienzle, G. Bushell, and T. Sculley. 2002. Antiserum raised against the Epstein-Barr virus BARF0 protein reacts to HLA-DR beta chain. Arch. Virol. 147:723-729. [PubMed] 53. Sheen, T. S., Y. T. Huang, Y. L. Chang, J. Y. Ko, C. S. Wu, Y. C. Yu, C. H. Tsai, and M. M. Hsu. 1999. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn. J. Cancer Res. 90:1285-1292. [PubMed] 54. Shimizu, N., H. Yoshiyama, and K. Takada. 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J. Virol. 70:7260-7263. [PubMed] 55. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182. [PubMed] 56. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712. [PubMed] 57. Smith, P. R., O. de Jesus, D. Turner, M. Hollyoake, C. E. Karstegl, B. E. Griffin, L. Karran, Y. Wang, S. D. Hayward, and P. J. Farrell. 2000. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J. Virol. 74:3082-3092. [PubMed] 58. Speck, P., and R. Longnecker. 2000. Infection of breast epithelial cells with Epstein-Barr virus via cell-to-cell contact. J. Natl. Cancer Inst. 92:1849-1851. [PubMed] 59. Sternas, L., T. Middleton, and B. Sugden. 1990. The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells. J. Virol. 64:2407-2410. [PubMed] 60. Sugiura, M., S. Imai, M. Tokunaga, S. Koizumi, M. Uchizawa, K. Okamoto, and T. Osato. 1996. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br. J. Cancer 74:625-631. [PubMed] 61. Takeuchi, H., R. Kobayashi, M. Hasegawa, and K. Hirai. 1996. Detection of latent infection by Epstein-Barr virus in peripheral blood cells of healthy individuals and in non-neoplastic tonsillar tissue from patients by reverse transcription-polymerase chain reaction. J. Virol. Methods 58:81-89. [PubMed] 62. Teramoto, N., A. Maeda, K. Kobayashi, K. Hayashi, T. Oka, K. Takahashi, K. Takada, G. Klein, and T. Akagi. 2000. Epstein-Barr virus infection to Epstein-Barr virus-negative nasopharyngeal carcinoma cell line TW03 enhances its tumorigenicity. Lab. Investig. 80:303-312. [PubMed] 63. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385. [PubMed] 64. van Beek, J., A. A. Brink, M. B. Vervoort, M. J. van Zijp, C. J. Meijer, A. J. van den Brule, and J. M. Middeldorp. 2003. In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without associated in vivo BARF0 protein expression in multiple EBV-associated disorders. J. Gen. Virol. 84:2647-2659. [PubMed] 65. Vincent, S., L. Marty, and P. Fort. 1993. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res. 21:1498. [PubMed] 66. Wiseman, S. M., N. Makretsov, T. O. Nielsen, B. Gilks, E. Yorida, M. Cheang, D. Turbin, K. Gelmon, and D. G. Huntsman. 2005. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103:1770-1777. [PubMed] 67. Xing, X., S. C. Wang, W. Xia, Y. Zou, R. Shao, K. Y. Kwong, Z. Yu, S. Zhang, S. Miller, L. Huang, and M. C. Hung. 2000. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6:189-195. [PubMed] 68. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127-137. [PubMed] 69. Yoshizaki, T., H. Sato, M. Furukawa, and J. S. Pagano. 1998. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA 95:3621-3626. [PubMed] 70. Young, L., C. Alfieri, K. Hennessy, H. Evans, C. O'Hara, K. C. Anderson, J. Ritz, R. S. Shapiro, A. Rickinson, E. Kieff, and J. I. Cohen. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085. [PubMed] 71. Young, L. S., and A. B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768. [PubMed] 72. Yu, D., B. Liu, T. Jing, D. Sun, J. E. Price, S. E. Singletary, N. Ibrahim, G. N. Hortobagyi, and M. C. Hung. 1998. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16:2087-2094. [PubMed] 73. Zaczek, A., B. Brandt, and K. P. Bielawski. 2005. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol. Histopathol. 20:1005-1015. [PubMed] 74. Zhang, J., H. Chen, G. Weinmaster, and S. D. Hayward. 2001. Epstein-Barr virus BamHI-A rightward transcript-encoded RPMS protein interacts with the CBF1-associated corepressor CIR to negatively regulate the activity of EBNA2 and NotchIC. J. Virol. 75:2946-2956. [PubMed] 75. Zhu, C. H., and F. E. Domann. 2002. Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth. Breast Cancer Res. Treat. 71:47-57. [PubMed]
|
This article has been 
